fda glp-1 enforcement news october 2025 Compounded GLP-1s are entering a new phase of scrutiny. With the targeting large-scale compounded manufacturing, patients are facing a moment where access, safety, and regulatory clarity all matter. In my Congress Introduces SAFE Drugs Act

Additionally, data on the use of GLP-1 therapies in geriatric populations remain limited

These claims focus on whether Mounjaro can cause or contribute to stomach paralysis, delayed gastric emptying, bowel obstruction, and other severe gastrointestinal events

Olson, Randy J

In December 2025, the administration also introduced the BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) model, a five year CMS Innovation Center (CMMI) model that intends to expand access to obesity drugs in Medicaid and Medicare by negotiating lower GLP-1 prices with manufacturers

10.4330/wjc.v17.i4.104717 61 PerleyM

Like they trust me